DIRAS2

Across TCGA pan-cancer cohorts, DIRAS2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DIRAS2 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DIRAS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DIRAS2 expression acts as an unfavorable survival marker.

LUAD, KIRP, and SARC are the cancer types where DIRAS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.068	0.680	<.001	20	view →
KIRP	OS	Median	All	0.178	0.885	<.001	18	view →
SARC	OS	Median	All	0.230	0.772	<.001	12	view →
LIHC	DFS	Median	All	0.077	0.555	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DIRAS2–LUAD (OS)

Open the LUAD breakdown →